PEA‑15 Contributes to the Clinicopathology and AKT‑regulated Cisplatin Resistance in Gastric Cancer

Oncology Reports - Greece
doi 10.3892/or.2018.6934
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

LncRNA MALAT1 Regulates the Cell Proliferation and Cisplatin Resistance in Gastric Cancer via PI3K/AKT Pathway

Cancer Management and Research
Oncology
2020English

Dampened PI3K/AKT Signaling Contributes to Cancer Resistance of the Naked Mole Rat

2020English

SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2008English

Effects of Taxol Resistance Gene 1 on the Cisplatin Response in Gastric Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Akt-Regulated Pathways in Prostate Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

RNF138 Confers Cisplatin Resistance in Gastric Cancer Cells via Activating Chk1 Signaling Pathway

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

AFAP1‑AS1 Induces Cisplatin Resistance in Non‑small Cell Lung Cancer Through PI3K/AKT Pathway

Oncology Letters
Cancer ResearchOncology
2019English

PKM2 Promotes Cell Migration and Inhibits Autophagy by Mediating PI3K/AKT Activation and Contributes to the Malignant Development of Gastric Cancer

Scientific Reports
Multidisciplinary
2017English

LncRNA TATDN1 Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Through TATDN1/miR-451/TRIM66 Axis

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy